Skip to main content
. Author manuscript; available in PMC: 2015 Sep 10.
Published in final edited form as: Addiction. 2010 Feb;105(2):343–355. doi: 10.1111/j.1360-0443.2009.02780.x

Table 3.

Continuous (past 4 weeks) and point-prevalence (past 1 week) post-treatment abstinence rates. Products with different superscript letters were significantly different (P < 0.05).

Treatments
0.3 mg nicotine cigarettes (n = 52)
 Nicotine lozenges (n = 60)
 0.05 mg nicotine cigarettes (n = 53)
# abstinent % # abstinent % # abstinent % P-value
Continuous abstinence
    1CO verified 11 21.2 21 35.0 23 43.4 0.0508
    2CO and cotinine verified 7 13.5 11 18.3 16 30.2 0.0913
CO verified point prevalence abstinence
Follow-up week
    1 18 34.6 25 41.7 22 41.5 0.6954
    2 17 32.7 25 41.7 29 54.7 0.0719
    4 12 23.1 22 36.7 23 43.4 0.0829
    6 12 23.1a 22 36.7a,b 25 47.2b 0.0357
CO and cotinine verified point prevalence abstinence
Follow-up week
    2 12 23.1a 16 26.7a 24 45.3b 0.0298
    4 8 15.4a 13 21.7a 21 39.6b 0.0120
    6 7 13.5a 12 20.0a,b 19 35.9b 0.0192
1

Carbon monoxide (CO) verified abstinence represents abstinence from cigarettes but usage of nicotine lozenge is allowed.

2

CO and cotinine verified represents abstinence from all nicotine-containing products, including nicotine lozenge.